A study reported that treatment of lung cancer cell lines with TKIs enriches the ALDHbright stem-like cells through EGFR-dependent activation of Notch3 and inhibition of EGFR kinase activity leads to an increase in ALDHbright cells [18]. The gene discussed is EGFR; the disease is lung carcinoma.